Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

ctDNA-guided chemo escalation does not improve recurrence-free survival in...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

ctDNA-guided chemo escalation does not improve recurrence-free survival in stage III colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type...

Dr Veronica Conca - University of Pisa, Pisa, Italy

Upfront modified FOLFOXIRI plus panitumumab improves OS in RAS/BRAF wild-type mCRC ( Dr Veronica Conca - University of Pisa, Pisa, Italy )

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible...

Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma ( Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer

Prof Sven Mahner - Ludwig Maximilian University of Munich, Munich, Germany

Primary cytoreductive surgery shows PFS benefit in advanced ovarian cancer ( Prof Sven Mahner - Ludwig Maximilian University of Munich, Munich, Germany )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Molecular assay may help identify NSCLC patients who could benefit from...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

Molecular assay may help identify NSCLC patients who could benefit from adjuvant chemotherapy ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract...

Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt...

Neoadjuvant gemcitabine and cisplatin improves OS in resectable biliary tract cancer ( Dr Thorsten Oliver Goetze - The University Cancer Center (UCT), Frankfurt, Germany )

Trastuzumab deruxtecan benefit for some advanced gastric cancers

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Trastuzumab deruxtecan benefit for some advanced gastric cancers ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

More from ecancer